CALCO

Synthetic peptide, 32 residues long formulated as a nasal spray.

Used in the treatment of symptomatic

Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments.

In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified.

It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents.

Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves.

Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.

Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts.

This leads to a net increase in bone mass and a reduction in plasma calcium levels.

It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption.

In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.

Salmon calcitonin is rapidly absorbed with bioavailability of 71% following subcutaneous injection and 66% following intramuscular injection in humans.

Via the nasal route, the bioavailability varies between 3-5% relative to Intramuscular.

Salmon calcitonin primarily undergoes degradation in the kidneys to form pharmacologically inactive metabolites.

It is also metabolized in the blood and the peripheral tissue.

Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.

elimination (terminal): Intramuscular. 58 minutes; SubQ 59-64 minutes; Nasal: ~18-23 minutes.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers.

While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans.

It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks.

Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response.

The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo.

The same may apply to

Intravenous, Intramuscular and Subcutaneous routes since the systemic exposure is higher in those cases.

Nausea is noticeable in some patients but tends to decrease with continued administration.

Rhinitis, headaches and back pain have also been reported among others.